Tumor genetic background influences immune/inflammatory infiltrate into the TME not only in the primary tumor, but also in metastatic lesions, as demonstrated by Vidotto et al. Indeed, the authors showed that in PTEN-loss prostate cancer, higher levels of Tregs were observed in liver metastases as compared to the primary lesion, and high levels of CD8+ cells were present in bone metastases [114]. Here, PTEN is linked to neoplasm.